Skin & hair

The Add-Ons Before You Reach a Biologic

Save

Chronic hives treatment doesn't jump straight from an antihistamine to an injectable biologic. In between sits a tier of add-on medicines — H2 blockers and montelukast among them — borrowed from reflux and asthma treatment and repurposed for skin that won't stop reacting. Here's what they actually do, how strong the evidence is, and how to tell whether one is worth keeping in the regimen.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Why H2 Blockers and Montelukast Enter the Picture

When up-dosing a second-generation antihistamine hasn't calmed chronic hives, guideline-based care often adds a second medicine before reaching for a biologic — an H2 blocker, montelukast, or both — as an add-on option for refractory urticaria, even though the evidence behind these particular add-ons is thinner than the evidence for the steps just before and after them 1. The logic behind adding a second medicine, rather than simply raising the first one further, is that these drugs act through different pathways than an H1-antihistamine, and combining pathways sometimes controls hives that one alone does not. That said, add-ons are a middle tier, not a destination: they are tried for a defined period, and if hives are still active, the plan generally moves on rather than accumulating more and more pills indefinitely.

Before Add-Ons: Making Sure Antihistamines Are Maxed Out First

Guideline-based chronic hives care moves in a specific order, and add-ons are not usually the first move. Antihistamine up-dosing — increasing a second-generation antihistamine well beyond its standard starting amount — comes before an H2 blocker or montelukast is added, because that step alone controls hives for many people without needing a second drug at all 1. Choosing the first antihistamine for hives matters less than many people expect, since the class as a whole is considered first-line and roughly interchangeable in evidence terms; what matters more is giving a chosen antihistamine, at an increased amount if needed, a real trial before assuming it has failed and moving on to something else.

H2 Blockers: Where Famotidine Fits Now

H2 blockers — where famotidine fits now, alongside older options in the same class — were originally developed for reflux and ulcers, and their role in chronic hives is as an add-on to an H1-antihistamine rather than a treatment on their own. Blocking histamine's H2 receptor addresses a different, smaller piece of the allergic reaction than the H1 blockade antihistamines provide, which is the rationale for combining the two rather than using an H2 blocker alone 1. For most people this add-on is low-risk to try, but it is exactly that — a trial, evaluated over a defined stretch of weeks rather than assumed to help indefinitely.

Montelukast: A Different Pathway, Weaker Evidence

Montelukast works on leukotrienes, an inflammatory signal separate from histamine, which is the rationale for adding it when an H1-antihistamine alone isn't controlling hives. Guideline authors group montelukast with H2 blockers as a refractory-disease add-on rather than as strong first-line evidence, and not everyone who tries it notices a difference 1. Because the evidence for montelukast in chronic hives is weaker and more mixed than the evidence for antihistamine up-dosing or for the biologic at the far end of the ladder, it tends to be tried, timed, and reassessed rather than continued automatically.

Choosing Between Them, or Trying Both

Guideline language treats H2 blockers and montelukast as parallel options rather than ranking one clearly above the other, which is part of why practice varies from one clinician to the next: some try one add-on before the other, some start both around the same time when hives are significantly affecting daily life, and there isn't strong evidence dictating a single correct order 1. What tends to matter more than which add-on comes first is giving each a defined trial — typically a matter of weeks — before deciding it isn't helping, rather than judging things off a single bad day that could just as easily reflect normal week-to-week fluctuation in how active the hives are.

When Add-Ons Aren't Enough: The Step After

When antihistamines don't touch your hives even after up-dosing and add-ons, chronic hives escalation moves toward omalizumab, an injectable biologic that targets IgE rather than histamine directly and is the option with the strongest trial evidence for antihistamine-refractory chronic hives 2. In placebo-controlled trials, people getting omalizumab had significantly better control of itch and hives than people getting placebo — the finding that makes it, rather than another round of add-ons, the guideline-recommended next step once the earlier tiers have had a fair trial 2. That represents a real shift in strategy: from combining several modestly-evidenced pills to a single, well-studied biologic aimed at a different part of the immune response.

Tracking Whether Any of This Is Actually Working

Because add-ons like H2 blockers and montelukast have modest, inconsistent evidence behind them, tracking response matters more than usual. A hives severity score such as the UAS7 urticaria activity score turns a subjective sense of 'about the same' into a number that can show whether an add-on is actually earning its place in the regimen or just adding another pill with no real benefit. Recording that score before starting an add-on and again a few weeks later is a simple way to keep the regimen honest, rather than accumulating medicines because none was ever formally stopped. A simple daily log of hives and itch, even without a formal scoring tool, accomplishes something similar: it turns a run of bad days into data a clinician can act on, instead of an impression that's hard to compare visit to visit.

Eventually Stepping Back Down

Chronic hives that go into remission don't necessarily need every add-on kept forever. Tapering hives treatment once hives have been quiet for a stretch is a normal part of the plan, usually removing medicines in something like the reverse order they were added — the least-proven add-ons first, the foundational antihistamine last — rather than stopping everything at once. Deciding when to stop hives medication is a conversation for the clinician who built the regimen in the first place, since restarting a taper that moved too fast is easier than managing a flare that came back unexpectedly.

Common questions

Not as reliably. Second-generation H1-antihistamines, especially at an increased amount, have the strongest evidence and are tried first. H2 blockers and montelukast are add-on options for hives that don't respond well enough to antihistamines alone, with evidence that is real but more mixed — some people notice a clear benefit, others don't.

It's a standard add-on option in guideline-based chronic hives care, generally used alongside an existing antihistamine rather than replacing it. Like any medicine, whether it's appropriate depends on someone's full health picture, which is a conversation for the prescribing clinician rather than a decision to make alone.

Tracking with a structured tool, such as a weekly hives severity score, is more reliable than judging day to day, since hives naturally fluctuate. Comparing a score from before an add-on was started to a score a few weeks later shows whether it's earning its place in the regimen.

The next guideline-recommended step is typically omalizumab, an injectable biologic with the strongest trial evidence for chronic hives that hasn't responded to antihistamines and add-ons. It targets a different part of the immune response than histamine-blocking drugs do, which is why it can help even when several pills haven't.

Often, yes, but tapering is usually done gradually and in a planned order rather than stopping everything at once. Chronic hives can flare again after stopping treatment, so working out a taper with the clinician managing the regimen is safer than discontinuing everything independently.

Related

Deciding about this?

A short, sourced overview to weigh with your clinician:

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When Hives Need Same-Day Attention

  • —Swelling of the lips, tongue, throat, or face alongside hives, or any difficulty breathing or swallowing
  • —Hives appearing together with dizziness, fainting, or a rapid heartbeat
  • —Hives that started shortly after a new medicine, food, or insect sting, especially with any breathing symptoms
  • —Hives lasting more than six weeks without a clear trigger, which moves it into chronic urticaria and warrants an evaluation

Hives with swelling of the face, lips, tongue, or throat, or any trouble breathing, is a medical emergency — call 911 or get to the nearest emergency room immediately.

This article is general health information, not medical advice. It cannot tell you whether an H2 blocker, montelukast, or any other add-on is right for your hives. Treatment decisions, including when to add or stop a medicine, should be made with the clinician managing your care.

References

  1. 1.Bernstein JA, Lang DM, Khan DA, et al. (2014). The diagnosis and management of acute and chronic urticaria: 2014 update. Journal of Allergy and Clinical Immunology. PMID 24766875 ✓Joint Task Force practice parameter recommending second-generation H1-antihistamines first-line with dose escalation, and add-on options, including H2 blockers and leukotriene receptor antagonists, for refractory chronic urticaria.
  2. 2.Maurer M, Rosén K, Hsieh HJ, et al. (2013). Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria. New England Journal of Medicine. doi:10.1056/NEJMoa1215372 ✓Phase 3 randomized trial showing omalizumab significantly improves itch and urticaria symptoms in patients with chronic idiopathic/spontaneous urticaria refractory to H1-antihistamines.

2 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy

← Back to the health library